Comprehensive Medical Weight Loss
Thirteen years ago, the AMA launched a strategic plan with three primary objectives, one of which was improving health outcomes related to prediabetes and hypertension. Notably, this plan was implemented one year before the AMA formally recognized obesity as a…
GLP-1 medications like semaglutide and tirzepatide can help people lose 15–25% of their body weight over 1–2 years. But like medicine for high blood pressure, these drugs only work while you’re taking them. If you stop, the weight usually comes…
As women move through their 40s and 50s, many start thinking more seriously about their long-term health—and for good reason. A new study published in JAMA Network Open by researchers at Tufts and Harvard reinforces something we’ve been teaching our…
I recently had the opportunity to attend and speak at the Obesity Medicine Association’s annual conference. It was inspiring to be surrounded by so many respected colleagues and experts in the field. While there was a lot of exciting new…
These days, there’s a lot of buzz around the new injectable weight loss medications. Wegovy® and Zepbound™ are making headlines because they help people lose a lot of weight—15% and 20% of body weight, respectively—and they even help with health…
For decades, people have been told that to lose weight, one must eat less and move more. This age-old adage is about as helpful as arguing about which came first, the chicken or the egg. Any weight loss strategy the…
We’re excited to introduce CNC e-Visits, a new way to connect with your provider for quick, efficient, and high-quality care—without the need for an in-person visit! Benefits of CNC e-Visits: ✅ Convenience: Get care from the comfort of your home—no…
GLP-1 medications like semaglutide and tirzepatide have revolutionized obesity treatment, helping patients achieve 10%-25% weight loss over one to two years. However, as with any medical weight-loss intervention, these medications are a tool—not a cure. Just as stopping blood pressure…
Wegovy: $499 / Month || Zepbound: $499 / Month As both Wegovy (semaglutide) and Zepbound (tirzepatide) are coming out of shortage, both manufacturers announced new options for cash-pay patients to expand access to these new weight loss treatments. If you…
On February 21st, 2025, the FDA declared that semaglutide (Wegovy / Ozempic) is no longer in shortage. This will have significant impact for patients currently being treated with compounded semaglutide. Read on to learn more about this decision, and about…
